We were delighted to talk to Diego Maselli (University of Texas Health Science Center at San Antonio, TX, US) around the effects of Body Mass Index (BMI) on response to the triple therapy of fluticasone furoate, umeclidinium, and vilanterol in patients with inadequately controlled asthma (Clinical Trial Identifier: NCT02924688).
The abstract ‘CAPTAIN: Effects of Body Mass Index (BMI) on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on Inhaled Corticosteroids/Long-acting b2-agonists (ICS/ LABA).’ (ABSTRACT NUMBER: 176) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
- What has the CAPTAIN trial taught us about the clinical utility of the single inhaler triple therapy of fluticasone furoate, umeclidinium, and vilanterol in the treatment of patients with uncontrolled asthma? (0:23)
- What were the results of your analysis of the CAPTAIN study data in subgroups defined by BMI? (1:18)
- What are the implications of these findings for asthma therapy? (3:06)
- What are the remaining unanswered questions regarding the use of this triple therapy? (3:50)
Disclosures: Diego Maselli discloses consulting fees from GSK, AstraZeneca, Sanofi/Regeneron and Amgen.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
Share this Video
Related Videos In Asthma
Antonio Spanevello: Research Highlights from 2021
We were delighted to talk with our Editorial Board member Professor Antonio Spanevello (University of Insubria, Varese, Italy) around his research highlights from 2021 in the field of airway inflammation and asthma. Question Is the evaluation of airway inflammation important in detecting the different phenotypes of bronchial asthma? (0:26) Disclosures: Antonio Spanevello has nothing to […]
Njira Lugogo, CHEST 2021: Tezepelumab for the Treatment of Severe, Uncontrolled Asthma
It was a pleasure to meet with Professor Njira Lugogo (University of Michigan, Ann Arbor, MI, USA) to discuss the findings from the NAVIGATOR study, investigating tezepelumab in adults and adolescents with severe, uncontrolled asthma (NCT03347279). The abstract ‘TEZEPELUMAB PRODUCES CLINICALLY MEANINGFUL RESPONSES ON PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA: RESULTS FROM […]
Njira Lugogo, CHEST 2021: Updates in Asthma Treatment
We were delighted to catch up with Professor Njira Lugogo (University of Michigan, Ann Arbor, MI, USA) around her presentation ‘Asthma Management: New Insights’, which was presented at CHEST 2021, 17-20 October 2021. Questions What has recent research taught us about the heterogeneity of asthma? (0:12) What are the most promising potential future biomarkers for […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!